Discovery of selective HDAC6 inhibitors driven by artificial intelligence and molecular dynamics simulation approaches
Open Access
- 12 May 2025
- journal article
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 15 (8) , 101338
Abstract
No abstract availableKeywords
Funding Information
- Hebei Medical University
- Hebei Provincial Department of Science and Technology (21372601D)
- Hebei Provincial Department of Science and Technology (BJ2025046)
- Hebei Provincial Department of Science and Technology (CYZD202501)
- National Natural Science Foundation of China (32100771)
This publication has 49 references indexed in Scilit:
- Advances in dual-targeting inhibitors of HDAC6 for cancer treatmentEuropean Journal of Medicinal Chemistry, 2024
- Activity of pure flavonoid-based green silver nano particles against breast cancer: A combined experimental and computational investigationJournal of Molecular Structure, 2024
- Curriculum vitae of HDAC6 in solid tumorsInternational Journal of Biological Macromolecules, 2023
- Repurposing of anti-lung cancer drugs as multi-target inhibitors of SARS-CoV-2 proteins: An insight from molecular docking and MD-simulation studyMicrobial Pathogenesis, 2022
- Compound–protein interaction prediction by deep learning: Databases, descriptors and modelsDrug Discovery Today, 2022
- Bisphenol A drives di(2-ethylhexyl) phthalate promoting thyroid tumorigenesis via regulating HDAC6/PTEN and c-MYC signalingJournal of Hazardous Materials, 2022
- Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigationEuropean Journal of Medicinal Chemistry, 2021
- Identification of new potent A1 adenosine receptor antagonists using a multistage virtual screening approachEuropean Journal of Medicinal Chemistry, 2020
- Recent advances in the discovery of potent and selective HDAC6 inhibitorsEuropean Journal of Medicinal Chemistry, 2018
- HDAC family: What are the cancer relevant targets?Cancer Letters, 2009